Background {#Sec1}
==========

Porcine circovirus (PCV) is a small, nonenveloped, icosahedral virus containing a circular single-stranded DNA genome, which is assigned to the Circoviridae family. PCV comprises with two genotypes, which are non-pathogenic PCV1 and pathogenic PCV2 \[[@CR1]\]. The former exist widely in PK-15 cells, and the latter is closely related with postweaning multisystemic wasting syndrome (PMWS) \[[@CR2]\], which mainly infect weaned pigs and fattening pigs. Nowadays, porcine circovirus type 2 (PCV2) has become one of the most important pathogens affecting the swine industry worldwide \[[@CR3]\]. PCV2 contains at least two major open reading frames (ORFs). ORF1 encodes the replication proteins (Rep and Rep') which involved in virus replication, and ORF2 encodes the capsid proteins (Cap) were found to be immunogenic which made them suitable for vaccine development \[[@CR4]\].

Currently, PCV2 vaccination is still an important method to combat porcine circovirus diseases (PCVD). At present, chimeric viruses, subunit vaccines, recombinant vaccines, genetic engineering vaccines and other kind of vaccines were researched at home and abroad. However, the most successful vaccine candidates were those based on the induction of an active immune response against the capsid protein of PCV2 \[[@CR5]--[@CR7]\].

Some domestic and international reports have showed that CpG motifs have the effect of immunostimulation as an immune adjuvant \[[@CR8], [@CR9]\]. CpG motifs can activate the immune system by enhancing the antigen presentation capacity of APC. The current research on CpG as immune adjuvant was mainly focused on the mouse and human disease. Based on the earlier research in the authors 'laboratory (Cheng KH, "Study on Series of DNA Vaccines Against Porcine Circovirus Type 2\[D\],"\[master's thesis QingDao Agricultural University, 2009\]), we first reported the CpG motifs as an adjuvant insert to the PCV2 DNA vaccine that could boost immunity in pigs \[[@CR10]\].

Our research and other research had showed that mouse could be infected by PCV2 and used as a PCV2 infected experimental model \[[@CR11], [@CR12]\]. In this study,we evaluate immune effect of PCV2 DNA vaccine with CpG motif on mice using the best CpG motif from our earlier research \[[@CR10]\], which can provide a great prospect for preventing and controlling PCVD,in order to give candidate vaccine evaluation model.

Methods {#Sec2}
=======

Viruses and vaccine {#Sec3}
-------------------

The titer of PCV2 strain SD on PK-15 cells (DQ478947) was 10^6.0^ TCID~50~/ml. PCV2 strain SD,DNA vaccine plasmid 18CpG-pVAX1-ORF2,plasmids pVAX1-ORF2 and pVAX1 were constructed by Cheng Kaihui and saved by Shandong Key Laboratory of Animal Disease Control & Breeding. PCV2 strain SD was also preserved in Chinese bacterium Preservation Center (CGMCC NO.5774).

Animal vaccination {#Sec4}
------------------

Six-week old female BALB/c mice (Shandong province Experimental Animal Centre, China) were divided randomly into four groups (10 mice/group), which were immunized intramuscular injection in legs by 18CpG-pVAX1-ORF2, pVAX1-ORF2, pVAX1 or PBS, respectively, and immunized again after 2 weeks (Table [1](#Tab1){ref-type="table"}). All mice were challenged intramuscularly with 0.2 mL PCV2 cells virulent strain SD (10^6.0^ TCID~50~/mL) after 4 weeks. Average daily gain was recorded everyday during the experiment. All mice experimental procedures were performed in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of People's Republic of China.Table 1Groups distribution and Immunization of six-week-old miceGroupsImmunized recombinant plasmidDosageI(Control)PBS0.2 mLIIpVAX10.2 mL(Plasmid concentration 500 μg/mL)IIIpVAX1-ORF20.2 mL(Plasmid concentration 500 μg/mL)IV18CpG-pVAX1-ORF20.2 mL(Plasmid concentration 500 μg/mL)

Physical signs studies {#Sec5}
----------------------

The change of body weight was recorded at the time of vaccinations, and before PCV2 cells virulent strain challenge. Average daily gain was calculated to evaluate the vaccine effection.

Assay of mice blood antibody levels {#Sec6}
-----------------------------------

The blood samples was collected at the time of vaccinations, 2 weekly intervals during immunity period and weekly after challenge until necropsy, respectively. The serum were separated and detected blood antibody levels with PCV2-dCap-ELISA kit (Tianjin ringpu biotechnology Limited by Share Ltd) according to the manufacturer's directions. The positive cutoff was set at S/P ≥ 0.25 when S/P = (OD~450~ of sample - OD~450~ mean of negative control)/(OD~450~ mean of positive control - OD~450~ mean of negative control).

Pathological and histopathology studies {#Sec7}
---------------------------------------

The mice were euthanized at 3 weeks after challenge and samples from the lung, spleen and liver were fixed in 10 % neutral-buffered formalin solution, and were sectioned and stained with hematoxylin and eosin (HE). Microscopic changes were determined by comparing the tissues of the challenged mice with those of the control-groups.

Assay of PCV2 distribution by Real-time PCR {#Sec8}
-------------------------------------------

Real-time PCR was used to detect the virus in the neck muscles, heart, liver, spleen, lung, kidney and blood. One pair of polymerase chain reaction (PCR) primers D1 5′-TTACCGGCGCACTTCGGCAG -3′ and D2 5′-ACTCCGTTGTCCCTGAGAT -3′ were designed using computer software (Primer Premier 5.0) according to the published sequence of the PCV2 in GenBank (DQ478947) to establish a fluorescent quantitative PCR assay for the detection of PCV2 (404 bp). The amplification was carried out in a 25 μL reaction containing 1 μM of each forward and reverse primer, 12.5 μL of SYBR Green I Mix (TaKaRa), 2 μL DNA templates, and ddH~2~O up to 25 μL. The PCR conditions were as follows: 95 °C for 10 min, followed by 30 cycles of amplification at 95 °C for 10 s, and 55°Cfor 10 s \[[@CR13]\]. The assays were repeated at least three times, with each experiment performed in triplicate.

Statistical analysis {#Sec9}
--------------------

All data were performed using SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). Statistical analyses were analyzed by two-way analysis of variance (ANOVA) followed by Tukey's post hoctest, respectively. Differences were considered significance at *p* \< 0.05.

Result {#Sec10}
======

Average daily gain (ADG) {#Sec11}
------------------------

Body weight was recorded at day 1 and 4 week, ADG of every mouse was calculated and statistical analyses were performed. The result showed that compared to the control mice (group I),there was no significant difference among groups (*p* ≥ 0.05), and the weight gain was not altered by vaccination in mice.

Assay of blood antibody detection {#Sec12}
---------------------------------

Porcine circovirus type 2 (PCV2)-antibody responses monitored by PCV2-ORF2 protein enzyme-linked immunosorbent assay. The antibody level of group III and IV was rised gradually after first immunization, and group IV showed an obvious rise after secondary immunization, while group III rised within a narrow range. However, the antibody of group IV was still up to 0.3097 at 4 week after secondary immunization, which was positive. Thus, the immune effect of DNA vaccine containing 18 CpG was better than other groups throughout the time after vaccination. After challenge with PCV2 strain SD, the antibody level of the four groups was all rised due to the anamnestic response in the vaccinated groups, and the highest level was appeared at 1 week after challenge. The antibody level of group IV was higher significantly than other groups (*p* \< 0.05), and decreased slowly along with time (Fig. [1](#Fig1){ref-type="fig"}). The results of mice blood antibody detection (S/P) was showed in Table [2](#Tab2){ref-type="table"}.Fig. 1Serum antibody level after immunization in mice Table 2Serum antibody level after immunization in mice (S/P)GroupsPre-immune bloodBlood after the first immunization two weeksBlood after the second immunization two weeksBlood after the second immunization four weeksBlood after injection one weekBlood after injection two weeksBlood after injection three weeksI0.15070.15100.16010.15000.23290.22060.1993II0.15070.16280.20520.18620.42490.30840.2426III0.15070.25760.30030.24170.59280.42670.3223IV0.15070.31270.43400.30970.67540.57950.5186

Clinical observation and pathological changes {#Sec13}
---------------------------------------------

All mice of group I and II becoming lean, almost emaciated and displayed splenomegaly, No obvious clinical signs and gross lesions were observed in the vaccinated group mice of group III and IV.

The alveolar walls thicked and inflammatory cells infiltrated in lung bronchia were showed in mice of group I (Fig. [2a](#Fig2){ref-type="fig"}). Interstitial pneumonia, and congestion were observed in alveolar interlobular interval and infiltration with inflammatory cells (Fig. [2b](#Fig2){ref-type="fig"}) while the hepatocyte showed slight atrophy and hemorrhage (Fig. [2j](#Fig2){ref-type="fig"}) in group II mice. A few of inflammatory cells were observed in alveoli of group III (Fig. [2c](#Fig2){ref-type="fig"}). Degenerative necrosis in kidney tubules and wider congestion in the glomeruli were observed in group I-III (Fig. [2e, f, g](#Fig2){ref-type="fig"}). Typical slight vacuoles granular degeneration was observed in hepatocyte of group I (Fig. [2i](#Fig2){ref-type="fig"}) and III (Fig. [2k](#Fig2){ref-type="fig"}), respectively. No obvious unusual changes were observed in lungs, kidney and liver of group IV (Fig. [2d, h, l](#Fig2){ref-type="fig"}). The result showed that the DNA vaccine containing 18 CpG could provide an effective immune protection.Fig. 2Histopathological changes in the lungs (A-D), kidney (E-H) and liver (I-L) of mice infected by PCV2 (HE). Mice of group I (PBS) showed alveolar walls were thick and inflammatory cells were in the lung bronchia (**a**). Mice of group II (pVAX1) showed interstitial pneumonia, and congestion was observed in alveolar interlobular interval and infiltration with inflammatory cells (**b**). A few of inflammatory cells were observed in alveoli of group III (pVAX1-ORF2) (**c**). Wider congestion in the glomeruli was observed in group I-III, and degenerative necrosis in kidney tubules were observed in group I and II (**e**, **f**). The typical or slight vacuoles granular degeneration was observed in hepatocyte of group I or III, respectively (**i**, **k**). The hepatocyte of group II showed slight atrophy (**j**). No obvious unusual changes were observed in lungs, liver and kidney of group IV (**d**, **h**, **l**). The scale bar is 100 mm

Quantitative analysis of PCV2 expression in tissues and blood {#Sec14}
-------------------------------------------------------------

The PCV2 contents in blood and different tissues were calculated at 1, 2 and 3 weeks after injection (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). The results showed that PCV2 were not detected in the position of injection which is neck muscles. Atthe first week after injection, while the PCV2 contents of groups III and IV were less than groups I and II (*p* \< 0.05). PCV2 were not detected in the tissues and blood of group IV at 3 weeks after injection, while the liver, spleen, kidney and blood have a few PCV2, which explained the virus was not eliminated completely. In addition, the amount of PCV2 in spleen was the highest in all the tissues and blood (Fig. [2](#Fig2){ref-type="fig"}).Table 3The testing result of PCV2 in the organs of micedaysGroupsheartliverspleenlungrenalmuscleblood7dI+++++++II+++++++III+++-+++IV+++++-+14dI+++++++II+++++++III+++-+-+IV+-+-+-+21dI+++++++II+++++++III-++-+-+IV\-\-\-\-\-\-- Fig. 3The distribution of virus in different organizations of different periods

Discussions {#Sec15}
===========

PCV2, the primary causative agent of PMWS, PRDC, mainly infected the weaned piglets (Allan et al., 1998), resulting in substantial economic losses to the pig industry. At present, there were not good drugs to treat with the diseases caused by PCV2. Thus, vaccine immunization has become a fundamental means and measures to prevent PCV2.

Nucleic acid vaccine is one of the hot spot of PCV2 vaccine researches. DNA vaccines may be capable of inducing immunity regardless of maternally derived antibodies \[[@CR14], [@CR15]\] and they have induced protective cellular and humoral immunity in preclinical models of infectious diseases. PCV2 Nucleic acid vaccine was first reported by Kamstrup \[[@CR16]\], they developed and investigated the potential of DNA vaccination approach to against PCV2. Mice were vaccinated three times by gene gun and all mice responded serologically by raising antibodies against PCV2. They found that vaccination based on DNA might offer opportunities for vaccination of piglets against PCV2.

However, DNA vaccine applications are limited due to the problems related to delivery, species of the immunized animals and degradation of plasmid DNA. To compensate for these limitations, numerous studies have explored methods to improve immune responses induced by DNA immunization by optimizing plasmid design, vaccine delivery systems and adjuvants \[[@CR17]\]. Adjuvants are of particular interest because they may enhance DNA delivery and increase the magnitude and duration of plasmid DNA expression \[[@CR18]\]. Guo (2015) reported the enhancement of the immunogenicity of porcine circovirus type 2 DNA vaccines by using a recombinant plasmid co-expressing capsid protein and porcine interleukin-6 in mice. Dong \[[@CR19]\] found that the mice co-inoculated with pVAX-PCV2-ORF2 plus pVAX-pIL-15 have higher humoral and cellular immune responses than the others. In addition, DNA plasmid bearing PCV2 ORF2 gene has a protective effect against challenge with PCV2 in mice which could be promoted with the utilization of pIL-15.Fu \[[@CR20]\] evaluated three adjuvants Ubiquitin (ub), the peptide binding truncated C-terminal portion of heat shock protein 70 (hsp70c) and interleukin-2 (IL-2) in PCV2 DNA vaccine, they found that ub is a superior adjuvant for PCV2 DNA vaccination than the hsp70c and IL-2 molecules. Chen \[[@CR21]\] evaluated two recombinant plasmids containing the ORF2 gene of porcine circovirus type 2 (PCV2) with or without porcine interleukin-18 (IL-18) and found that the plasmid pBudCE4.1-ORF2/IL18 may be an effective approach for increasing the immunogenicity of PCV2 DNA vaccine.

Our previous research demonstrated that CpG motifs as an adjuvant could boost the humoral and cellular immunity of pigs to against PCV2, especially in terms of cellular immunity \[[@CR10]\]. This study evaluated the adjuvant of CpG motifs to PCV2 DNA vaccine and mainly detected the serum antibody levels in mice by ELISA. The results showed that the antibody levels of immune groups were increased, especially the nucleic acid vaccine containing 18 CpG, kept at a higher level throughout the immunization and decreased slowly, after challenge, it increased rapidly and could maintain a longer time.

The result of quantitative real-time PCR showed that PCV2 was replicated in the tissues of mice, while it was eliminated gradually in immune groups. Moreover, the content of PVC2 in spleen of all the tissues was the highest. The result of autopsy declared obvious lesions were appeared in group I and II, and minimal lesion was appeared in group III. No obvious unusual changes were observed in group IV.

Conclusions {#Sec16}
===========

In conclusion, the nucleic acid vaccine containing 18 CpG can build up resistibility immunity and reduce immune organ damage on mice. which has a wide prospect for preventing and controlling PCV2 infection.
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